RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+16.06%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.94B
AUM Growth
+$2.94B
(+14%)
Cap. Flow
+$60.2M
Cap. Flow
% of AUM
2.04%
Top 10 Holdings %
Top 10 Hldgs %
43.94%
Holding
91
New
27
Increased
20
Reduced
25
Closed
12
Top Buys
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$80M |
| 2 |
uniQure
QURE
|
$61.4M |
| 3 |
Labcorp
LH
|
$51.8M |
| 4 |
Xeris Biopharma Holdings
XERS
|
$45.8M |
| 5 |
MOR
MorphoSys AG American Depositary Shares
MOR
|
$38.5M |
Top Sells
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$78.7M |
| 2 |
Puma Biotechnology
PBYI
|
$74.6M |
| 3 |
Penumbra
PEN
|
$65.6M |
| 4 |
Regenxbio
RGNX
|
$40.9M |
| 5 |
Abbott
ABT
|
$39.4M |
Sector Composition
| 1 | Healthcare | 93% |
| 2 | Financials | 1.03% |
| 3 | Technology | 0.19% |
| 4 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
| $268M | 9.11% | 15,978,580 -1,245,848 | -7% | -$20.9M |
|
2
Amicus Therapeutics
FOLD
$2.34B
| $164M | 5.58% | 10,511,732 -226,926 | -2% | -$3.54M |
|
3
Atara Biotherapeutics
ATRA
$84.6M
| $152M | 5.15% | 4,126,617 -109,400 | -3% | -$4.02M |
|
|
IMGN
4
DELISTED
Immunogen Inc
IMGN
| $120M | 4.07% | 12,315,942 +2,613,460 | +27% | +$25.4M |
|
5
Xencor
XNCR
$580M
| $116M | 3.96% | 3,147,043 -57,300 | -2% | -$2.12M |
|
|
6
Regenxbio
RGNX
$451M
| $112M | 3.81% | 1,561,175 -569,797 | -27% | -$40.9M |
|
|
ALDR
7
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $103M | 3.49% | 6,505,766 | – | – |
|
|
WCG
8
DELISTED
Wellcare Health Plans, Inc.
WCG
| $87.4M | 2.97% | 355,009 +12,700 | +4% | +$3.13M |
|
9
Wave Life Sciences
WVE
$1.53B
| $85.9M | 2.92% | 2,244,507 +6,900 | +0.3% | +$264K |
|
|
BOLD
10
DELISTED
Audentes Therapeutics, Inc
BOLD
| $85.2M | 2.89% | 2,228,656 +920,130 | +70% | +$35.2M |
|
|
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
| $80M | 2.72% | +1,758,600 | New | +$80M |
|
12
Fate Therapeutics
FATE
$120M
| $75.5M | 2.56% | 6,655,962 | – | – |
|
13
InflaRx
IFRX
$108M
| $65.4M | 2.22% | 2,027,700 +1,176,600 | +138% | +$37.9M |
|
14
Centene
CNC
$14.3B
| $62.6M | 2.13% | 507,985 -51,815 | -9% | -$6.38M |
|
|
15
uniQure
QURE
$896M
| $61.4M | 2.09% | +1,624,400 | New | +$61.4M |
|
|
ALXN
16
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $60.7M | 2.06% | 489,300 +84,500 | +21% | +$10.5M |
|
17
LivaNova
LIVN
$3.08B
| $59.9M | 2.03% | 599,788 +81,500 | +16% | +$8.14M |
|
|
DCPH
18
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $58.1M | 1.97% | 1,477,080 +655,800 | +80% | +$25.8M |
|
19
argenx
ARGX
$43.6B
| $55.8M | 1.9% | 673,300 +434,700 | +182% | +$36M |
|
20
ICU Medical
ICUI
$3.15B
| $54.1M | 1.84% | 184,172 -9,300 | -5% | -$2.73M |
|
|
21
Labcorp
LH
$23.1B
| $51.8M | 1.76% | +288,400 | New | +$51.8M |
|
22
Insmed
INSM
$28.8B
| $48.1M | 1.63% | 2,033,492 -132,870 | -6% | -$3.14M |
|
|
SYNH
23
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $46M | 1.56% | 981,673 -544,431 | -36% | -$25.5M |
|
|
24
Xeris Biopharma Holdings
XERS
$1.26B
| $45.8M | 1.56% | +2,412,642 | New | +$45.8M |
|
|
BLUE
25
DELISTED
bluebird bio
BLUE
| $42.1M | 1.43% | 268,500 +1,400 | +0.5% | +$220K |
|